Global and Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, Status and Forecast 2021-2027
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Prevention
1.2.3 Physiotherapy
1.2.4 Immunity Therapy
1.3 Market by Application
1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Center
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2016-2027)
2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Regions
2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Industry Dynamic
2.3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends
2.3.2 Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
2.3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
2.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue
3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
3.4 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
3.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2020
3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
3.6 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
3.7 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2022-2027)
5 Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application
5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
6.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
6.2.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
6.3.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
6.4.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
7.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
7.2.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
7.3.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
7.4.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
9.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
9.2.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
9.3.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
9.4.1 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Achaogen
11.1.1 Achaogen Company Details
11.1.2 Achaogen Business Overview
11.1.3 Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.1.4 Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.1.5 Achaogen Recent Development
11.2 Adenium Biotech
11.2.1 Adenium Biotech Company Details
11.2.2 Adenium Biotech Business Overview
11.2.3 Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.2.4 Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.2.5 Adenium Biotech Recent Development
11.3 Aridis Pharmaceuticals
11.3.1 Aridis Pharmaceuticals Company Details
11.3.2 Aridis Pharmaceuticals Business Overview
11.3.3 Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.3.4 Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.3.5 Aridis Pharmaceuticals Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.4.4 AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.4.5 AstraZeneca Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.5.4 Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.5.5 Bayer Recent Development
11.6 Cardeas Pharma
11.6.1 Cardeas Pharma Company Details
11.6.2 Cardeas Pharma Business Overview
11.6.3 Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.6.4 Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.6.5 Cardeas Pharma Recent Development
11.7 Destiny Pharma
11.7.1 Destiny Pharma Company Details
11.7.2 Destiny Pharma Business Overview
11.7.3 Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.7.4 Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.7.5 Destiny Pharma Recent Development
11.8 Dong-A Socio Holdings
11.8.1 Dong-A Socio Holdings Company Details
11.8.2 Dong-A Socio Holdings Business Overview
11.8.3 Dong-A Socio Holdings Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.8.4 Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.8.5 Dong-A Socio Holdings Recent Development
11.9 Lakewood-Amedex
11.9.1 Lakewood-Amedex Company Details
11.9.2 Lakewood-Amedex Business Overview
11.9.3 Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.9.4 Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.9.5 Lakewood-Amedex Recent Development
11.10 MedImmune
11.10.1 MedImmune Company Details
11.10.2 MedImmune Business Overview
11.10.3 MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.10.4 MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.10.5 MedImmune Recent Development
11.11 Meiji Seika Pharma
11.11.1 Meiji Seika Pharma Company Details
11.11.2 Meiji Seika Pharma Business Overview
11.11.3 Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.11.4 Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.11.5 Meiji Seika Pharma Recent Development
11.12 Merck & Co
11.12.1 Merck & Co Company Details
11.12.2 Merck & Co Business Overview
11.12.3 Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.12.4 Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.12.5 Merck & Co Recent Development
11.13 Motif Bio
11.13.1 Motif Bio Company Details
11.13.2 Motif Bio Business Overview
11.13.3 Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.13.4 Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.13.5 Motif Bio Recent Development
11.14 Nabriva Therapeutics
11.14.1 Nabriva Therapeutics Company Details
11.14.2 Nabriva Therapeutics Business Overview
11.14.3 Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.14.4 Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.14.5 Nabriva Therapeutics Recent Development
11.15 Polyphor
11.15.1 Polyphor Company Details
11.15.2 Polyphor Business Overview
11.15.3 Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.15.4 Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.15.5 Polyphor Recent Development
11.16 Shionogi & Co
11.16.1 Shionogi & Co Company Details
11.16.2 Shionogi & Co Business Overview
11.16.3 Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.16.4 Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.16.5 Shionogi & Co Recent Development
11.17 Tetraphase Pharmaceuticals
11.17.1 Tetraphase Pharmaceuticals Company Details
11.17.2 Tetraphase Pharmaceuticals Business Overview
11.17.3 Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.17.4 Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.17.5 Tetraphase Pharmaceuticals Recent Development
11.18 The Medicines Company
11.18.1 The Medicines Company Company Details
11.18.2 The Medicines Company Business Overview
11.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.18.5 The Medicines Company Recent Development
11.18 Theravance Biopharma
.1 Theravance Biopharma Company Details
.2 Theravance Biopharma Business Overview
.3 Theravance Biopharma Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
.4 Theravance Biopharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
.5 Theravance Biopharma Recent Development
11.20 Wockhardt
11.20.1 Wockhardt Company Details
11.20.2 Wockhardt Business Overview
11.20.3 Wockhardt Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.20.4 Wockhardt Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.20.5 Wockhardt Recent Development
11.21 Zavante Therapeutics
11.21.1 Zavante Therapeutics Company Details
11.21.2 Zavante Therapeutics Business Overview
11.21.3 Zavante Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
11.21.4 Zavante Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021)
11.21.5 Zavante Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesTable 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Prevention
Table 3. Key Players of Physiotherapy
Table 4. Key Players of Immunity Therapy
Table 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2022-2027)
Table 11. Ventilator Associated Pneumonia (VAP) Therapeutics Market Trends
Table 12. Ventilator Associated Pneumonia (VAP) Therapeutics Market Drivers
Table 13. Ventilator Associated Pneumonia (VAP) Therapeutics Market Challenges
Table 14. Ventilator Associated Pneumonia (VAP) Therapeutics Market Restraints
Table 15. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2020)
Table 18. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
Table 22. Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Achaogen Company Details
Table 63. Achaogen Business Overview
Table 64. Achaogen Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 65. Achaogen Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Achaogen Recent Development
Table 67. Adenium Biotech Company Details
Table 68. Adenium Biotech Business Overview
Table 69. Adenium Biotech Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 70. Adenium Biotech Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Adenium Biotech Recent Development
Table 72. Aridis Pharmaceuticals Company Details
Table 73. Aridis Pharmaceuticals Business Overview
Table 74. Aridis Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 75. Aridis Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Aridis Pharmaceuticals Recent Development
Table 77. AstraZeneca Company Details
Table 78. AstraZeneca Business Overview
Table 79. AstraZeneca Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 80. AstraZeneca Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 81. AstraZeneca Recent Development
Table 82. Bayer Company Details
Table 83. Bayer Business Overview
Table 84. Bayer Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 85. Bayer Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Bayer Recent Development
Table 87. Cardeas Pharma Company Details
Table 88. Cardeas Pharma Business Overview
Table 89. Cardeas Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 90. Cardeas Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Cardeas Pharma Recent Development
Table 92. Destiny Pharma Company Details
Table 93. Destiny Pharma Business Overview
Table 94. Destiny Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 95. Destiny Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Destiny Pharma Recent Development
Table 97. Dong-A Socio Holdings Company Details
Table 98. Dong-A Socio Holdings Business Overview
Table 99. Dong-A Socio Holdings Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Dong-A Socio Holdings Recent Development
Table 101. Lakewood-Amedex Company Details
Table 102. Lakewood-Amedex Business Overview
Table 103. Lakewood-Amedex Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 104. Lakewood-Amedex Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 105. Lakewood-Amedex Recent Development
Table 106. MedImmune Company Details
Table 107. MedImmune Business Overview
Table 108. MedImmune Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 109. MedImmune Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 110. MedImmune Recent Development
Table 111. Meiji Seika Pharma Company Details
Table 112. Meiji Seika Pharma Business Overview
Table 113. Meiji Seika Pharma Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 114. Meiji Seika Pharma Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 115. Meiji Seika Pharma Recent Development
Table 116. Merck & Co Company Details
Table 117. Merck & Co Business Overview
Table 118. Merck & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 119. Merck & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 120. Merck & Co Recent Development
Table 121. Motif Bio Company Details
Table 122. Motif Bio Business Overview
Table 123. Motif Bio Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 124. Motif Bio Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 125. Motif Bio Recent Development
Table 126. Nabriva Therapeutics Company Details
Table 127. Nabriva Therapeutics Business Overview
Table 128. Nabriva Therapeutics Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 129. Nabriva Therapeutics Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 130. Nabriva Therapeutics Recent Development
Table 131. Polyphor Company Details
Table 132. Polyphor Business Overview
Table 133. Polyphor Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 134. Polyphor Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 135. Polyphor Recent Development
Table 136. Shionogi & Co Company Details
Table 137. Shionogi & Co Business Overview
Table 138. Shionogi & Co Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 139. Shionogi & Co Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 140. Shionogi & Co Recent Development
Table 141. Tetraphase Pharmaceuticals Company Details
Table 142. Tetraphase Pharmaceuticals Business Overview
Table 143. Tetraphase Pharmaceuticals Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 144. Tetraphase Pharmaceuticals Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 145. Tetraphase Pharmaceuticals Recent Development
Table 146. The Medicines Company Company Details
Table 147. The Medicines Company Business Overview
Table 148. The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Product
Table 149. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2016-2021) & (US$ Million)
Table 150. The Medicines Company Recent Development
Table 151. Theravance Biopharma Company Details
Table 152. Theravance Biopha